Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Azitra, Inc.

Get SEC filing alerts via email and in your feed for Azitra, Inc.

AZTR

Azitra, Inc.

About Azitra, Inc.

Azitra, Inc. is a clinical-stage biopharmaceutical company developing precision dermatology therapies using engineered proteins and live biotherapeutic products derived from a proprietary microbial library of over 1,500 bacterial strains. Focusing on genetically engineered Staphylococcus epidermidis, Azitra creates topical treatments targeting rare and chronic skin diseases, leveraging AI-driven strain screening and licensed genetic engineering technologies to deliver therapeutic proteins directly into the skin for improved disease management.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Azitra, Inc.

1
1
Azitra, Inc. Azitra Reports $3.9 Million Net Loss and $10.4 Million Fundraising in Latest 10-Q Filing

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Azitra, Inc. Azitra, Inc. Reports $11M Net Loss and No Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Azitra, Inc. Azitra Reports No Revenue and Increased Losses in Third Quarter 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Azitra, Inc. Azitra Reports Zero Revenue and Increased Losses in Q2 and First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Azitra, Inc. Azitra Reports $3.07 Million Net Loss in Q1 2025, Faces Funding Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Azitra, Inc. Azitra Reports $8.97M Net Loss and 99% Revenue Decline for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Azitra, Inc. Azitra Reports Significant Changes in Revenue, Expenses, and Financial Position for Q3 and Nine Months Ended September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments